Abstract
Clinical question:
Is gabapentin associated with pain relief in people with chronic neuropathic pain?
Bottom line:
Oral gabapentin (1200-3600 mg/d for 4-12 weeks) for patients with moderate or severe neuropathic pain from postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN) is associated with pain reduction of at least 50% in 14% to 17% more patients than placebo.
MeSH terms
-
Administration, Oral
-
Amines / adverse effects
-
Amines / therapeutic use*
-
Analgesics / adverse effects
-
Analgesics / therapeutic use*
-
Cyclohexanecarboxylic Acids / adverse effects
-
Cyclohexanecarboxylic Acids / therapeutic use*
-
Diabetic Neuropathies / drug therapy*
-
Gabapentin
-
Humans
-
Meta-Analysis as Topic
-
Neuralgia, Postherpetic / drug therapy*
-
Off-Label Use
-
gamma-Aminobutyric Acid / adverse effects
-
gamma-Aminobutyric Acid / therapeutic use*
Substances
-
Amines
-
Analgesics
-
Cyclohexanecarboxylic Acids
-
gamma-Aminobutyric Acid
-
Gabapentin